[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518507":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":45,"responsibleParty":217,"collaborators":25,"id":219,"slug":25,"hasResults":220,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":25,"eligibilityCriteria":224,"healthyVolunteers":220,"sex":225,"minAge":226,"maxAge":25,"enrollmentInfo":227,"targetDuration":25,"studyType":230,"phases":231,"briefSummary":233,"conditions":234,"keywords":25,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":247},{"fullName":5,"class":6},"Genentech, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation Cohort","EXPERIMENTAL","Participants in successive cohorts will receive escalating doses of RO7566802, as an intravenous (IV) infusion on Day 1 of each 21-day cycle followed by RO7566802 in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.",[13,14],"Drug: RO7566802","Drug: Atezolizumab",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose Expansion Cohort","Participants with select solid tumors will receive a recommended dose of RO7566802, determined in Dose Escalation phase, as an IV infusion in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","RO7566802","RO7566802 solution for infusion will be administered as specified in each treatment arm.",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Atezolizumab","Atezolizumab solution for infusion will be administered as specified in each treatment arm.",[9,16],[31],"Tecentriq®",[33],{"name":34,"affiliation":35,"role":36},"Clinical Trials","Hoffmann-La Roche","STUDY_DIRECTOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Reference Study ID Number: GO44431 https:\u002F\u002Fforpatients.roche.com\u002F","CONTACT","888-662-6728 (U.S. Only)","global-roche-genentech-trials@gene.com",{"name":44,"role":40,"phone":25,"phoneExt":25,"email":25},"Fastest response: use the inquiry form. No email attachments. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[46,59,69,78,88,98,108,119,129,140,150,159,165,175,184,193,199,208],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":25},"University of Alabama at Birmingham (UAB)","RECRUITING","Birmingham","Alabama","35233","United States",{"type":54,"coordinates":55},"Point",[56,57],-86.80249,33.52066,{"lat":57,"lon":56},{"facility":60,"status":48,"city":61,"state":62,"zip":63,"country":52,"cosmosGeoPoint":64,"geoPoint":68,"contacts":25},"Yale Cancer Center","New Haven","Connecticut","06520",{"type":54,"coordinates":65},[66,67],-72.92816,41.30815,{"lat":67,"lon":66},{"facility":70,"status":48,"city":71,"state":71,"zip":72,"country":52,"cosmosGeoPoint":73,"geoPoint":77,"contacts":25},"Icahn School of Medicine at Mount Sinai (ISMMS)","New York","10029",{"type":54,"coordinates":74},[75,76],-74.00597,40.71427,{"lat":76,"lon":75},{"facility":79,"status":48,"city":80,"state":81,"zip":82,"country":52,"cosmosGeoPoint":83,"geoPoint":87,"contacts":25},"The Ohio State University","Columbus","Ohio","43221-3502",{"type":54,"coordinates":84},[85,86],-82.99879,39.96118,{"lat":86,"lon":85},{"facility":89,"status":48,"city":90,"state":91,"zip":92,"country":52,"cosmosGeoPoint":93,"geoPoint":97,"contacts":25},"Magee-Woman's Hospital","Harrisburg","Pennsylvania","17109",{"type":54,"coordinates":94},[95,96],-76.88442,40.2737,{"lat":96,"lon":95},{"facility":99,"status":48,"city":100,"state":101,"zip":102,"country":52,"cosmosGeoPoint":103,"geoPoint":107,"contacts":25},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":54,"coordinates":104},[105,106],-86.78444,36.16589,{"lat":106,"lon":105},{"facility":109,"status":48,"city":110,"state":111,"zip":112,"country":113,"cosmosGeoPoint":114,"geoPoint":118,"contacts":25},"St Vincent's Hospital Sydney","Darlinghurst","New South Wales","2010","Australia",{"type":54,"coordinates":115},[116,117],151.21925,-33.87939,{"lat":117,"lon":116},{"facility":120,"status":48,"city":121,"state":122,"zip":123,"country":113,"cosmosGeoPoint":124,"geoPoint":128,"contacts":25},"Peter Maccallum Cancer Centre","Melbourne","Victoria","3000",{"type":54,"coordinates":125},[126,127],144.96332,-37.814,{"lat":127,"lon":126},{"facility":130,"status":48,"city":131,"state":132,"zip":133,"country":134,"cosmosGeoPoint":135,"geoPoint":139,"contacts":25},"British Columbia Cancer Agency - 600 10th Ave W","Vancouver","British Columbia","V5Z 4E6","Canada",{"type":54,"coordinates":136},[137,138],-123.11934,49.24966,{"lat":138,"lon":137},{"facility":141,"status":48,"city":142,"state":143,"zip":144,"country":134,"cosmosGeoPoint":145,"geoPoint":149,"contacts":25},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 1Z5",{"type":54,"coordinates":146},[147,148],-79.39864,43.70643,{"lat":148,"lon":147},{"facility":151,"status":48,"city":152,"state":25,"zip":153,"country":152,"cosmosGeoPoint":154,"geoPoint":158,"contacts":25},"National University Hospital","Singapore","119074",{"type":54,"coordinates":155},[156,157],103.85007,1.28967,{"lat":157,"lon":156},{"facility":160,"status":48,"city":152,"state":25,"zip":161,"country":152,"cosmosGeoPoint":162,"geoPoint":164,"contacts":25},"National Cancer Centre","168583",{"type":54,"coordinates":163},[156,157],{"lat":157,"lon":156},{"facility":166,"status":48,"city":167,"state":25,"zip":168,"country":169,"cosmosGeoPoint":170,"geoPoint":174,"contacts":25},"Addenbrooke's Hospital","Cambridge","CB2 0QQ","United Kingdom",{"type":54,"coordinates":171},[172,173],0.11667,52.2,{"lat":173,"lon":172},{"facility":176,"status":48,"city":177,"state":25,"zip":178,"country":169,"cosmosGeoPoint":179,"geoPoint":183,"contacts":25},"Leicester Royal Infirmary","Leicester","LE1 5WW",{"type":54,"coordinates":180},[181,182],-1.13169,52.6386,{"lat":182,"lon":181},{"facility":185,"status":48,"city":186,"state":25,"zip":187,"country":169,"cosmosGeoPoint":188,"geoPoint":192,"contacts":25},"St Bartholomew's Hospital","London","EC1A 7BE",{"type":54,"coordinates":189},[190,191],-0.12574,51.50853,{"lat":191,"lon":190},{"facility":194,"status":48,"city":186,"state":25,"zip":195,"country":169,"cosmosGeoPoint":196,"geoPoint":198,"contacts":25},"Sarah Cannon Research Institute","W1G 6AD",{"type":54,"coordinates":197},[190,191],{"lat":191,"lon":190},{"facility":200,"status":48,"city":201,"state":25,"zip":202,"country":169,"cosmosGeoPoint":203,"geoPoint":207,"contacts":25},"Churchill Hospital","Oxford","OX3 7LJ",{"type":54,"coordinates":204},[205,206],-1.25596,51.75222,{"lat":206,"lon":205},{"facility":209,"status":48,"city":210,"state":25,"zip":211,"country":169,"cosmosGeoPoint":212,"geoPoint":216,"contacts":25},"The Royal Marsden hospital","Sutton","SM2 5PT",{"type":54,"coordinates":213},[214,215],-0.2,51.35,{"lat":215,"lon":214},{"type":218,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100518507",false,"NCT06031441","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* Life expectancy \\>=3 months, in the investigator's judgment\n* Adequate hematologic and end-organ function\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that has progressed after available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care\n* Measurable disease per RECIST v1.1\n* Tumor specimen availability, for certain cohorts\n\nExclusion Criteria:\n\n* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to Cycle 1 Day 1, with certain exceptions\n* Active hepatitis B or C\n* Active tuberculosis\n* Positive test for human immunodeficiency virus (HIV) infection\n* Administration of a live, attenuated vaccine (e.g., Flumist) within 4 weeks prior to RO7566802 infusion\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Active or history of autoimmune disease\n* Prior allogeneic stem cell or organ transplantation\n* Uncontrolled tumor-related pain\n* Significant cardiovascular disease\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":228,"type":229},250,"ESTIMATED","INTERVENTIONAL",[232],"PHASE1","This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.",[235,236,237],"Locally Advanced Solid Tumors","Recurrent Solid Tumors","Metastatic Solid Tumors","2026-06-26",{"date":240,"type":241},"2026-06-29","ACTUAL",{"date":243,"type":241},"2023-11-27",{"date":245,"type":229},"2027-12-31",{"name":5,"class":6},18]